Marketwatch out with the story about Epix Pharma (EPIX) receipt of a letter from the Food and Drug Administration (FDA) that sent shares soaring 17% on Monday. Get this: the letter DID NOT approve Vasovist, the company’s blood-pool imaging agent in the US. What was important here was that the FDA said it would not need additional clinical trials conducted. Explaining the news, EPIX President Andrew Uprichard said in a statement, “The FDA has now accepted that the image acquisition in the four previously conducted Phase III studies was of sufficient quality to potentially provide substantial evidence of the efficacy of Vasovist.” Vasovist is sold in 32 countries outside of the U.S., including Canada and all 27 member states of the European Union. Epix does not have any other products on the market.

Forbes publishing on Ceragon (CRNT). It seems shares have reached a year-high trading range on the heels of an upgrade and positive notes from analysts predicting solid growth for the Israeli communications equipment company. First Albany had recently upgraded the stock positing, “The key reason for our upgrade is our belief that Ceragon’s relationship with Nokia (NOK) and Siemens (SI) should continue through 2008, and possibly beyond, easing our earlier doubts about the relationship beyond 2007.”

CIBC out positively on NICE (NICE). CIBC believes earnings and revenue forecasts are intact with a possible upside surprise this quarter for the security company.

Haaretz/The Marker out with comments from Morgan Stanley that the Israeli economy is on fire. Even after posting growth of 6.1% in the first quarter of 2007, “growth could accelerate down the line this year, if domestic demand continues to climb. “

Share with others:

Related posts

• No related posts.